[1]
|
Hindricks, G., Potpara, T., Dagres, N., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 42, 373-498. https://doi.org/10.1093/eurheartj/ehaa612
|
[2]
|
John-Camm, A., Simantirakis, E., Goette, A., et al. (2017) Atrial High-Rate Episodes and Stroke Prevention. EP Europace, 19, 169-179. https://doi.org/10.1093/europace/euw279
|
[3]
|
陈颖. 利尿合剂对慢性心力衰竭患者炎症因子的干预作用研究[J]. 中国疗养医学, 2017, 26(12): 1319-1320.
|
[4]
|
Andrade, J., Khairy, P., Dobrev, D., et al. (2014) The Clinical Profile and Pathophysiology of Atrial Fibrillation: Relationships among Clinical Features, Epidemiology, and Mechanisms. Circulation Research, 114, 1453-1468.
https://doi.org/10.1161/CIRCRESAHA.114.303211
|
[5]
|
Miragoli, M. and Glukhov, A.V. (2015) Atrial Fibrillation and Fibrosis: Beyond the Cardiomyocyte Centric View. BioMed Research International, 2015, Article ID: 798768. https://doi.org/10.1155/2015/798768
|
[6]
|
Lau, D.H., Linz, D. and Sanders, P. (2019) New Findings in Atrial Fibrillation Mechanisms. Cardiac Electrophysiology Clinics, 11, 563-571. https://doi.org/10.1016/j.ccep.2019.08.007
|
[7]
|
郑金轩, 赵继义. 心外膜脂肪组织对心房颤动影响的研究进展[J]. 医学综述, 2019, 25(14): 2811-2815.
|
[8]
|
Zou, R., Yang, M., Shi, W., et al. (2018) Analysis of Genes Involved in Persistent Atrial Fibrillation: Comparisons of “Trigger” and “Substrate” Differences. Cellular Physiology and Biochemistry, 47, 1299-1309.
https://doi.org/10.1159/000490225
|
[9]
|
侯婷婷, 刘广忠, 陶源, 等. 心房颤动与心房重构研究的最新进展[J]. 现代生物医学进展, 2017, 17(35): 6972-6975.
|
[10]
|
Qin, M., Zeng, C. and Liu, X. (2019) The Cardiac Autonomic Nervous System: A Target for Modulation of Atrial Fibrillation. Clinical Cardiology, 42, 644-652. https://doi.org/10.1002/clc.23190
|
[11]
|
Carnagarin, R., Kiuchi, M.G., Ho, J.K., et al. (2018) Sympathetic Nervous System Activation and Its Modulation: Role in Atrial Fibrillation. Frontiers in Neuroscience, 2018, Article ID: 121058. https://doi.org/10.3389/fnins.2018.01058
|
[12]
|
Grunnet, M., Bentzen, B.-H., Sorensen, U.-S., et al. (2012) Cardiac ion Channels and Mechanisms for Protection against Atrial Fibrillation. Reviews of Physiology, Biochemistry and Pharmacology, 1621-1658.
|
[13]
|
Korantzopoulos, P., Letsas, K.P., Tse, G., et al. (2018) Inflammation and Atrial Fibrillation: A Comprehensive Review. Journal of Arrhythmia, 34, 394-401. https://doi.org/10.1002/joa3.12077
|
[14]
|
Scott, L., Li, N. and Dobrev, D. (2019) Role of Inflammatory Signaling in Atrial Fibrillation. International Journal of Cardiology, 287, 195-200. https://doi.org/10.1016/j.ijcard.2018.10.020
|
[15]
|
Harada, M., Van Wagoner, D.R. and Nattel, S. (2015) Role of Inflammation in Atrial Fibrillation Pathophysiology and Management. Circulation Journal, 79, 495-502. https://doi.org/10.1253/circj.CJ-15-0138
|
[16]
|
Ren, J.F., Marchlinski, F.E. and Callans, D.J. (2004) Left Atrial Thrombus Associated with Ablation for Atrial Fibrillation: Identification with Intracardiac Echocardiography. Journal of the American College of Cardiology, 43, 1861-1867.
https://doi.org/10.1016/j.jacc.2004.01.031
|
[17]
|
Docherty, K.-F., Vaduganathan, M., Solomon, S.-D., et al. (2020) Sacubitril/Valsartan: Neprilysin Inhibition 5 Years after PARADIGM-HF. JACC Heart Fail, 8, 800-810. https://doi.org/10.1016/j.jchf.2020.06.020
|
[18]
|
Hanefeld-Fox, L., Lissette, J., Rebecca, H., et al. (2018) Sacubitril/Valsartan-Associated Small Bowel Ileus. American Journal of Therapeutics, 25, E705-E706. https://doi.org/10.1097/MJT.0000000000000720
|
[19]
|
Weir, R.-A.-P. (2019) Sacubitril/Valsartan and Mexiletine: A Proarrhythmic Combination? Cardiology, 142, 4-6.
https://doi.org/10.1159/000497071
|
[20]
|
Ilana, F., Lam, C., Talreja, O., et al. (2020) Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia. Journal of Pharmacy Practice, 33, 696-699. https://doi.org/10.1177/0897190019828915
|
[21]
|
Vodovar, N., Helene, N., Jean-Marie, L., et al. (2017) Sacubitril/Valsartan in PARADIGM-HF. The Lancet. Diabetes & Endocrinology, 5, 495-496. https://doi.org/10.1016/S2213-8587(17)30177-8
|
[22]
|
陆益, 胡伟, 尹桂芝, 等. 诺欣妥对难治性心力衰竭患者心室重构及预后的影响研究[J]. 现代生物医学进展, 2019, 19(13): 2498-2501.
|
[23]
|
秦丽英, 李平宝, 范尧, 等. 诺欣妥对持续性房颤合并慢性心衰患者心功能和生活质量的影响[J]. 北方药学, 2020, 17(1): 133-134.
|
[24]
|
Li, L.-Y., Lou, Q., Liu, G.-Z., et al. (2020) Sacubitril/Valsartan Attenuates Atrial Electrical and Structural Remodelling in a Rabbit Model of Atrial Fibrillation. European Journal of Pharmacology, 881, Article ID: 173120.
https://doi.org/10.1016/j.ejphar.2020.173120
|
[25]
|
De Vecchis, R., Paccone, A. and Di Maio, M. (2020) Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan. Cardiology Research, 11, 213-218. https://doi.org/10.14740/cr1073
|
[26]
|
De Vecchis, R., Paccone, A. and Di Maio, M. (2020) Favorable Effects of Sacubitril/Valsartan on the Peak Atrial Longitudinal Strain in Patients with Chronic Heart Failure and a History of One or More Episodes of Atrial Fibrillation: A Retrospective Cohort Study. Journal of Clinical Medicine Research, 12, 100-107. https://doi.org/10.14740/jocmr4076
|
[27]
|
Thomas, H.E. and Olgin, J.E. (2007) Atrial Fibrosis and the Mechanisms of Atrial Fibrillation. Heart Rhythm, 4.
https://doi.org/10.1016/j.hrthm.2006.12.040
|
[28]
|
李发鹏, 甘天翊, 姜涛, 等. 基质金属蛋白酶-9及组织抑制因子-1在老年犬持续性心房颤动心房组织中表达[J]. 中华实用诊断与治疗杂志, 2012, 26(3): 223-226.
|
[29]
|
王文俊, 纪亚梅. 金属蛋白酶组织抑制因子-1对心室重构影响的研究进展[J]. 临床合理用药杂志, 2012, 5(18): 167.
|
[30]
|
Sun, H.P., Kristine, C.O., Chen, G., et al. (2016) Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. Circulation, 133, 2038-2049. https://doi.org/10.1161/CIRCULATIONAHA.115.020226
|
[31]
|
董闻平, 蒋金金. 血清MMP-9 TIMP-1浓度及左房内径与心房颤动类型的关系[J]. 中国药物与临床, 2012, 12(8): 1029-1030.
|
[32]
|
Suo, Y., Yuan, M., Li, H., et al. (2019) Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients with Atrial Fibrillation and in Pressure Overload-Induced Mice. Frontiers in Pharmacology, 2019, Article ID: 101285. https://doi.org/10.3389/fphar.2019.01285
|
[33]
|
Zile, M.R., O’Meara, E., Claggett, B., et al. (2019) Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients with HFrEF. Journal of the American College of Cardiology, 73, 795-806.
https://doi.org/10.1016/j.jacc.2018.11.042
|